Stains & CD markers
HMB45


Last author update: 10 July 2024
Last staff update: 10 July 2024

Copyright: 2002-2024, PathologyOutlines.com, Inc.

PubMed Search: HMB45

Umberto Maccio, M.D., M.Sc., M.B.A.
Page views in 2024 to date: 1,471
Cite this page: Maccio U. HMB45. PathologyOutlines.com website. https://www.pathologyoutlines.com/topic/stainsHMB45.html. Accessed November 27th, 2024.
Definition / general
Essential features
  • Monoclonal antibody that targets gp100, a premelanosome protein
  • Expressed in immature and in activated melanocytes
  • Used for evaluating maturation in primary melanocytic lesions
  • Usually combined with other melanocytic markers and not used alone as a screening marker for melanoma
  • Typical aberrant expression in some tumors without melanocytic differentiation (angiomyolipoma, perivascular epithelioid cell tumor [PEComa], lymphangioleiomyomatosis, TFE and TFEB rearranged renal cell carcinoma)
Pathophysiology
Interpretation
  • Cytoplasmic stain
  • Stains immature melanocytes
  • Gradient of maturation in benign nevus: diminution of HMB45 from surface (HMB45+, immature) toward base (HMB45-, mature) (Semin Diagn Pathol 2022;39:239)
  • Typically no maturation in melanoma
Uses by pathologists
  • Melanocytic marker for diagnosis of primary and metastatic melanoma (increased diagnostic accuracy in combination with other markers like SOX10, MelanA / MART1, S100, MITF, tyrosinase) (Int J Mol Sci 2022;23:5911)
  • Distinction between dermal component of cutaneous nevus (negative) and cutaneous melanoma (positive) (Int J Mol Sci 2022;23:5911)
    • Caution
      • Benign blue nevi typically positive for HMB45
      • Deep penetrating nevi often show HMB45 expression
      • Halo nevi may show aberrant HMB45 expression in up to 50% of cases (J Cutan Pathol 2021;48:519)
      • Desmoplastic melanomas are negative or only focally positive for HMB45
  • Evaluating sentinel lymph nodes for melanoma (Semin Diagn Pathol 2008;25:116)
  • For diagnosis of melanocytic lesions usually combined with other markers (sensitivity: S100 >> MelanA > HMB45; specificity: HMB45 > MelanA >> S100) (Semin Diagn Pathol 2022;39:239)
  • Distinction between melanoma with epithelioid morphology (HMB45+) and other epithelioid tumors (HMB45-) (Diagnostics (Basel) 2020;10:233)
  • Distinction between melanoma in situ (HMB45+) and mammary or extramammary Paget disease (HMB45-) (Virchows Arch 1996;429:371)
  • Distinction between metastasis of melanoma (HMB45+) and carcinoma (HMB45-) in panel with other markers (Hum Pathol 2004;35:217)
  • Distinction between angiomyolipoma (HMB45+) and tumor with similar morphology (HMB45-) (e.g., leiomyoma or angiolipoma) (Am J Surg Pathol 2015;39:349)
  • Distinction between epithelioid angiomyolipoma / epithelioid PEComa (HMB45+) and tumors with similar morphology (HMB45-) (e.g., clear cell carcinoma of the kidney and urothelial carcinoma with sarcomatoid differentiation) (Am J Surg Pathol 2001;25:65)
  • Distinction between lymphangioleiomyomatosis (HMB45+) and other cystic lesions of the lung (HMB45-) (Appl Immunohistochem Mol Morphol 2022;30:108)
  • Distinction between melanoma (HMB45+) in adrenal gland and adrenal cortical carcinoma (HMB45-) in combination with other markers (Medicine (Baltimore) 2017;96:e8956)
Microscopic (histologic) images

Contributed by Umberto Maccio, M.D., M.Sc., M.B.A.
Melanoma metastasis Melanoma metastasis Melanoma metastasis

Melanoma metastasis

Compound nevus Compound nevus

Compound nevus


Compound nevus

Compound nevus

Cutaneous melanoma Cutaneous melanoma

Cutaneous melanoma

Angiomyolipoma Angiomyolipoma

Angiomyolipoma

Cytology images

Images hosted on other servers:
Missing Image

Thyroid, metastatic melanoma

Positive staining - normal
Positive staining - disease
Negative staining
Sample pathology report
  • Lymph node, biopsy:
    • Metastatic melanoma involving one lymph node (1/1) (see comment)
    • Comment: The submitted biopsy material shows fragments of lymph node tissue with infiltration by discohesive epithelioid neoplastic cells exhibiting marked cytological atypia, high mitotic activity and the presence of widespread necrosis. Their immunohistochemical profile demonstrates strong and diffuse positivity for HMB45, SOX10, S100 and MelanA and negativity for AE1 / AE3 (by positive internal control), consistent with the diagnosis of melanoma.
Board review style question #1
Which statement about HMB45 is correct?

  1. HMB45 can be used as marker alone to diagnose a melanoma in metastatic setting
  2. HMB45 combined with other makers (e.g., S100) can be helpful in diagnosing melanoma
  3. In nonneoplastic tissues, HMB45 expression is limited only to fetal or neonatal melanocytes
  4. Melanocytic lesion with HMB45+ dermal component is always consistent with melanoma
Board review style answer #1
B. HMB45 combined with other makers (e.g., S100) can be helpful in diagnosing melanoma. HMB45 is a relatively specific marker but should be combined with other markers for diagnosing a melanoma. Answer D is incorrect because other melanocytic lesions (e.g., blue nevi) can be positive for HMB45. Answer A is incorrect because HMB45 alone is neither sensitive nor specific for melanoma (i.e., melanomas can be negative for HMB45 and other tumors such as PEComas can be positive for HMB45). Answer C is incorrect because HMB45 can be also expressed in reactive melanocytes (e.g., in case of inflammatory skin disorders).

Comment Here

Reference: HMB45
Board review style question #2

A renal tumor shows a mixed morphology with mature adipose tissue, epithelioid cells and thick walled vessels. Immunohistochemistry for HMB45 is shown in figure above. SMA is also positive, whereas AE1 / AE3, PAX8 and CAIX are negative (not shown). Which is the most likely diagnosis?

  1. Adrenal cortical carcinoma
  2. Angiomyolipoma
  3. Clear cell renal cell carcinoma
  4. Metastatic melanoma
Board review style answer #2
B. Angiomyolipoma. The morphology is consistent with a tumor with 3 components without atypia, mitotic activity or necrosis, which in this anatomic location is suggestive of angiomyolipoma. Immunohistochemistry for HMB45 is positive, which combined with the immunohistochemical profile provided above is diagnostic for angiomyolipoma. Answer D is incorrect because the morphology described is not typical for melanoma and HMB45 alone is not specific for melanoma as it can be expressed in other tumors. Answer C is incorrect because although some renal cell carcinomas (e.g., TFE and TFEB rearranged renal cell carcinoma) can express HMB45, clear cell carcinomas are typically negative for HMB45 and express PAX8 and CAIX. Answer A is incorrect because adrenal cortical carcinomas are typically negative for HMB45, although they express MelanA.

Comment Here

Reference: HMB45
Board review style question #3
Which of the following tumors is typically positive for HMB45?

  1. Angiolipoma
  2. Desmoplastic melanoma
  3. Oncocytoma
  4. TFE rearranged renal cell carcinoma
Board review style answer #3
D. TFE rearranged renal cell carcinoma. Rearrangements of genes of the MiT family (MITF, TFE, TFEB) lead typically to overexpression of premelanosome protein gp100, resulting in positivity for HMB45. Answer B is incorrect because desmoplastic melanomas are most commonly negative for HMB45. Answer C is incorrect because HMB45 is typically negative in oncocytic tumors of the kidney. Answer A is incorrect because HMB45 is typically positive in angiomyolipoma but not in angiolipoma.

Comment Here

Reference: HMB45
Back to top
Image 01 Image 02